Check out your Company Bowl for anonymous work chats.
Come work for an Alphabet company. Veeps are our greatest investment, so we go beyond a paycheck to invest in your future and financial wellbeing. We're hiring!
Come work for an Alphabet company. Veeps are our greatest investment, so we go beyond a paycheck to invest in your future and financial wellbeing. We're hiring!
Meet Kezia! This #WomensHistoryMonth we’re spotlighting women at Verily and the work they’re doing to advance precision health. First up is Kezia Cook-Robinson, Sr. Privacy Counsel, our vBlack ERG Lead, and Mentor for National Science and Technology Medals Foundation's program for STEM students from underrepresented communities. When we asked her what part of her job excites her most, she said: "Everything!" Kezia shared thoughts about the International Women's Day theme #EmbraceEquity: “I always say that everything we do is a team effort. 'Embrace equity' means that we must all work together to ensure that the opportunity to live your best life is afforded to everyone and everybody no matter their race, ethnicity, gender, or socio-economic status. We must all work on ourselves and collectively together to believe and execute on the fact that we all have the right to live and have equitable access to resources that will make it our best life.”
Meet Kezia! This #WomensHistoryMonth we’re spotlighting women at Verily and the work they’re doing to advance precision health. First up is Kezia Cook-Robinson, Sr. Privacy Counsel, our vBlack ERG Lead, and Mentor for National Science and Technology Medals Foundation's program for STEM students from underrepresented communities. When we asked her what part of her job excites her most, she said: "Everything!" Kezia shared thoughts about the International Women's Day theme #EmbraceEquity: “I always say that everything we do is a team effort. 'Embrace equity' means that we must all work together to ensure that the opportunity to live your best life is afforded to everyone and everybody no matter their race, ethnicity, gender, or socio-economic status. We must all work on ourselves and collectively together to believe and execute on the fact that we all have the right to live and have equitable access to resources that will make it our best life.”
A look inside precision medicine: New approaches to clinical research bring the potential to reduce costs and increase study diversity, while generating robust evidence. But, we must get data quality right. Amy Abernethy, our President, Product Development & Chief Medical Officer noted: "You have to deal with the data quality challenges that come from combining datasets such as data conflicts from multiple source datasets representing the same variable, which is something we’re working to advance as an industry.” Read more about RWD trends in Inside Precision Medicine, including the opportunity to create next generation trial designs that are more efficient and inclusive:
Broadening the Scope of Clinical Trials: The Changing Role of Real-World Evidence
LISTEN NOW: AI is only as good as the data that trains it. This is one of the lessons Dr. Lily Peng, Verily Director of Product Management, learned from her work on AI for diabetic retinopathy while at Google. The solution helped to screen the growing number of diabetic patients in India, showing how medical AI could benefit healthcare challenges. Hear more in NEJM Group's AI Grand Rounds podcast. #HealthTech #AIforHealth #DiabeticRetinopothy
Dr. Lily Peng: AI for Ophthalmology and the Challenges of AI in the Real World | NEJM AI Grand Rounds
The lack of diversity and representation in clinical trials continues to contribute to disparities in healthcare. Verily's Dr. Vindell Washington, Joe Franklin, Dr. Erich S. Huang, MD, PhD, Dr. Jessica Mega, MD MPH, and Dr. Amy Abernethy lay a foundation for how to approach DEI principles in study conduct in order to pursue more generalizable evidence that leads to better outcomes. Learn more in the paper “Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone,” published in American Society for Clinical Pharmacology & Therapeutics #PrecisionHealth #HealthEquity #BlackHistoryMonth #Verily
Verily on LinkedIn: Diversity, Equity and Inclusion in Clinical Research: a Path Towards...
Women continue to be underrepresented in cardiovascular research. Project Baseline by Verily and the American Heart Association have joined forces to launch #ResearchGoesRed, an initiative to help close the gap and make sure women are represented. Learn more:
Research Goes Red | Baseline by Verily & American Heart Association
Did you see our Super Bowl ad? We’re so excited to see Dexcom’s #SuperBowl commercial debuting the U.S. launch of #DexcomG7! The new continuous glucose monitoring (CGM) system, developed in partnership with Verily, is small and discreet, but yet a powerful solution designed to help people with diabetes get personalized insights for better care management. Learn more:
One of the smallest, most discreet Continuous Glucose Monitoring (CGM) Systems receives FDA Clearance | Verily Life Sciences
In this STAT feature, Casey Ross goes in depth on Stephen Gillett, Verily's new CEO, providing an up close look into his leadership and highlighting where we're headed next as we work to bridge research and care. The piece really captures our journey and Stephen’s commitment to focus and achieving impact at scale. Join us! verily.com/careers
Verily taps a Starbucks veteran and 'Warcraft' master
Today, we announced our expanded collaboration with Otsuka Pharmaceutical Companies (U.S.) on innovative clinical trials solutions to accelerate research in major depressive disorder (MDD). “These new recruitment and participant engagement capabilities offer the promise to include more participants in clinical research and to accelerate timelines to get treatments to patients faster,” said Amy Abernethy, President of Product Development & Chief Medical Officer at Verily. Read more:
Otsuka and Verily Expand Collaboration on Novel Clinical Trials Solutions to Accelerate Research in Major Depressive Disorder
Tune In: Season 2, Episode 5 of #ItsNotMagic is out now! Dr. Amy Abernethy is known for modernizing the FDA’s approach to big data. Now as Verily's President of Product Development and Chief Medical Officer, and a member of Sixth Street’s Scientific Advisory Board, she’s exploring approaches to real-world data and developing tools to bring advanced therapeutics to patients. Amy joins host David Stiepleman, as well as Sixth Street’s Vice Chairman, R. Martin Chavez, to discuss her contributions to transforming FDA processes and how today’s scientific advancements can lead toward improved public health outcomes. #Verily #PrecisionHealth
https://sixthstreet.com/podcasts/amy-abernethy-president-of-product-development-and-chief-medical-officer-of-verily/